1-9 of 9
Klaus Wethmar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

“As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Andrew F. Berdel, Julian Ronnacker, Daniela V. Wenge, Lina Kolloch, Philipp Berning, Linus Angenendt, Tobias Brix, Annette Westermann, Klaus Wethmar, Torsten Kessler, Andrea Kerkhoff, Rolf M. Mesters, Christian Reicherts, Jan-Henrik Mikesch, Wolfgang E. Berdel, Georg Lenz, Christoph Schliemann, Matthias Stelljes
Journal: Blood
Blood (2024) 144 (Supplement 1): 4242.
https://doi.org/10.1182/blood-2024-193666
Published: 2024
Journal Articles

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Anjali Cremer, Maher Hanoun, Ralph Wäsch, Simon Raffel, Klaus Wethmar, Andreas Viardot, Walter Fiedler, Knut Wendelin, Lore Marretta, Wolfram Jung, Roland Schroers, Vladan Vucinic, Monika Brüggemann, Stefan Schwartz, Hubert Serve, Nicola Goekbuget
Journal: Blood
Blood (2024) 144 (Supplement 1): 1436.
https://doi.org/10.1182/blood-2024-202270
Published: 2024
Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Matthias Stelljes, Nael Alakel, Ralph Wäsch, Sebastian Scholl, Kathrin Nachtkamp, Andreas Rank, Mathias Haenel, Bernd Spriewald, Maher Hanoun, Sonja Martin, Katjana Schwab, Julian Knaden, Lena Reiser, Julia Marx, Klaus Wethmar, Tim Sauer, Wolfgang E. Berdel, Georg Lenz, Monika Brüggemann, Simon Raffel, Nicola Goekbuget
Journal: Blood
Blood (2022) 140 (Supplement 1): 510–512.
https://doi.org/10.1182/blood-2022-162235
Published: 2022
Journal Articles

A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse

Andrew F. Berdel, Christoph Rollig, Martin Wermke, Linus Angenendt, Leo Ruhnke, Jan-Henrik Mikesch, Teresa Hemmerle, Klaus Wethmar, Torsten Kessler, Mirjam Gerwing, Daniel Hescheler, Michael Schäfers, Wolfgang Hartmann, Bianca Altvater, Claudia Rossig, Georg Lenz, Matthias Stelljes, Bjoern Rueter, Dario Neri, Wolfgang E. Berdel, Christoph Schliemann
Journal: Blood
Blood (2021) 138 (Supplement 1): 2345.
https://doi.org/10.1182/blood-2021-145859
Published: 2021
Journal Articles

Characteristics and Outcome of Elderly Patients (> 55 Years) with Acute Lymphoblastic Leukemia (ALL)

Daniela V. Wenge, Klaus Wethmar, Corinna Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf M. Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brüggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Journal: Blood
Blood (2021) 138 (Supplement 1): 3365.
https://doi.org/10.1182/blood-2021-146459
Published: 2021
Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, Nael Alakel, Ralph Wäsch, Sebastian Scholl, Kathrin Nachtkamp, Andreas Rank, Mathias Haenel, Bernd Spriewald, Maher Hanoun, Sonja Martin, Katjana Schwab, Julian Knaden, Julia Marx, Klaus Wethmar, Tim Sauer, Wolfgang E. Berdel, Georg Lenz, Martin Dugas, Nicola Goekbuget, Monika Brueggemann, Simon Raffel
Journal: Blood
Blood (2021) 138 (Supplement 1): 2300.
https://doi.org/10.1182/blood-2021-145553
Published: 2021
Journal Articles

First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, MD, Simon Raffel, MD, Ralph Wäsch, Sebastian Scholl, Mustafa Kondakci, MD, Andreas Rank, PD Dr, Mathias Haenel, MD, Sonja Martin, MD, Katjana Schwab, MD, Julian Knaden, Klaus Wethmar, MD, Tim Sauer, MD, Wolfgang E. Berdel, Prof., MD, Georg Lenz, Martin Dugas, Monika Brüggemann, MD, Nicola Goekbuget, MD, Nael Alakel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-136920
Published: 2020
Journal Articles

Temporal autoregulation during human PU.1 locus SubTAD formation

Daniel Schuetzmann, Carolin Walter, Boet van Riel, Sabrina Kruse, Thorsten König, Tabea Erdmann, Alexander Tönges, Eric Bindels, Andre Weilemann, Claudia Gebhard, Klaus Wethmar, Chiara Perrod, Julia Minderjahn, Michael Rehli, Ruud Delwel, Georg Lenz, Stefan Gröschel, Martin Dugas, Frank Rosenbauer
Journal: Blood
Blood (2018) 132 (25): 2643–2655.
https://doi.org/10.1182/blood-2018-02-834721
Published: 2018
Includes: Supplemental data
Journal Articles

Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation

Georg Varga, Sandra Balkow, Martin K. Wild, Andrea Stadtbaeumer, Mathias Krummen, Tobias Rothoeft, Tetsuya Higuchi, Stefan Beissert, Klaus Wethmar, Karin Scharffetter-Kochanek, Dietmar Vestweber, Stephan Grabbe
Journal: Blood
Blood (2006) 109 (2): 661–669.
https://doi.org/10.1182/blood-2005-12-023044
Published: 2006
Includes: Supplemental data